External broker reports(aggregated public sources), Nirmal Bang

Nirmal Bang

External broker reports(aggregated public sources)

A Relationship Beyond Broking

Nirmal Bang, one of the leading stock broking companies in India, caters to retail and institutional clients by offering them a range of financial products and services, including equities, derivatives, commodities, currency derivatives, mutual funds, IPOs, insurance, depository services and PMS.

Nirmal Bang is drawn from a diversity of professional backgrounds, and blend of experience, skill and dedication is shared with its clients. Nirmal Bang emphasizes adequate, thorough research local and world-wide developments, balancing these with the astute discovery of intrinsic values, synergies and growth. The aim is simply to help the investors to maximize their returns.

Equity Bottom-Up

<div><div><div><div><ul><li>ROSSARI has taken some price hikes from March’22 in order to cope with the ongoing inflationary challenges.</li><li>Formulations business is the core strength of ROSSARI’s business model and inability to pass on the cost impact would mean margin pressure for two more quarters</li></ul><ul style="list-style-type: none;"><li> </li></ul></div></div></div></div><div><div><div><div><ul><li>On a consolidated basis, the management has guided for Rs20bn revenue and Rs2.5bn EBITDA for FY23.</li></ul></div></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

ROSSARI has taken some price hikes from March’22 in order to cope with the ongoing inflationary challenges.Formulations business is the core strength of ROSSARI’s business model and inability to pass on the cost impact would mean margin pressure for two more quarters On a consolidated basis, the management has guided for Rs20bn revenue and Rs2.5bn EBITDA for FY23.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Rossari Biotech: Complete Pass-Through Is a Challenge in Formulations Biz

<div><div><div><div><ul><li>4QFY22 earnings performance: ROSSARI’s 4QFY22 consolidated revenue growth of 101% YoY was broadly in line with our estimate.</li></ul><div><div><div><div><ul><li>HPPC/TSC/AHN grew by 180%/25%/17% YoY, including acquisitions. Unitop and Tristar revenue came in at Rs1,240mn and Rs495mn, respectively in 4QFY22, with EBITDA margin coming in at ~15% and ~12%, respectively.</li></ul><div><div><div><div><ul><li>The share of HPPC revenue increased from 50% in 4QFY21 to 69% in 4QFY22.</li></ul></div></div></div></div></div></div></div></div></div></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

4QFY22 earnings performance: ROSSARI’s 4QFY22 consolidated revenue growth of 101% YoY was broadly in line with our estimate.HPPC/TSC/AHN grew by 180%/25%/17% YoY, including acquisitions. Unitop and Tristar revenue came in at Rs1,240mn and Rs495mn, respectively in 4QFY22, with EBITDA margin coming in at ~15% and ~12%, respectively.The share of HPPC revenue increased from 50% in 4QFY21 to 69% in 4QFY22.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Rossari Biotech - Complete Pass-Through Is a Challenge in Formulations Biz

External broker reports(aggregated public sources), Edelweiss Broking Limited

Edelweiss

Edelweiss Broking Limited

Edelweiss Broking Limited is an Indian Financial services company based in Mumbai, India. The company is a subsidiary of Edelweiss Group. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

<ul><li>Input cost inflation continues to weigh on margins.</li></ul><div class="content-highlight"><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></div>

Input cost inflation continues to weigh on margins.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Rossari  Biotech Ltd | Q3FY22 Result Update

<p>Robust organic growth; acquisitions open new avenues</p><div class="content-highlight"><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></div>

Robust organic growth; acquisitions open new avenuesContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Rossari  Biotech Ltd. | Q2FY22 Result Update

<p>Unitop acquisition to foster synergistic growth</p><div class="content-highlight"><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></div>

Unitop acquisition to foster synergistic growthContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

India

Rossari Biotech Limited manufactures specialty chemicals, textile, and animal health and nutritional products. The Company offers personal care, soaps, detergents, paints and coatings, and water treatment chemicals, as well as produces cotton, polyester, acrylic, and other textile specialty products. Rossari Biotech serves customers worldwide.

Rossari Biotech (ROSSARI IN)

Rossari Biotech: Complete Pass-Through Is a Challenge in Formulations Biz

We hosted Rossari Biotech’s (ROSSARI) management at our Annual Investor Conference in order to understand the overall demand outlook across segments

Nirmal Bang

Rossari Biotech - Complete Pass-Through Is a Challenge in Formulations Biz

RM inflation and increase in other costs like solvents, power & fuel etc has affected the margin profile of the business meaningfully for the last...

Nirmal Bang

Rossari Biotech Ltd | Q3FY22 Result Update

Input cost inflation continues to weigh on margins

Edelweiss

Rossari Biotech Ltd. | Q2FY22 Result Update

Robust organic growth; acquisitions open new avenues

Edelweiss

Rossari Biotech Ltd Rs Event Update

Unitop acquisition to foster synergistic growth

Edelweiss